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Forkhead transcription factors (FoxOs) play a pivotal role in
controlling cellular proliferation and survival. The cellular level
of these factors is tightly regulated through the phosphoinosit-
ide 3-kinase/Akt and ubiquitin-mediated degradation. How-
ever, the ubiquitin ligases responsible for the degradation of
FoxO1 and the relevance of this regulation to smooth muscle
cell (SMC) proliferation and survival have not been fully identi-
fied. Here we showed that overexpression of C terminus of
Hsc70-interacting protein (CHIP) promoted ubiquitination and
degradation of FoxO1 in SMCs in response to tumor necrosis
factor-. Both the U-box (containing ubiquitin ligase activity)
and the charged (essential for FoxO1 binding) domains within
CHIP were required for CHIP-mediated FoxO1 down-regula-
tion. Moreover, interaction and ubiquitination of FoxO1 by
CHIP depended on phosphorylation of FoxO1 at Ser-256. Fur-
thermore, overexpression of CHIP repressed FoxO1-mediated
transactivation and its proapoptotic function following tumor
necrosis factor- treatment. In contrast, knockdownofCHIPby
small interfering RNA enhanced FoxO1-mediated transactiva-
tion and its effect on SMC proliferation and survival. Taken
together, our data indicate that CHIP is a negative regulator of
FoxO1 activity through ubiquitin-mediated degradation, and
inhibition of CHIP may serve as a potential therapeutic target
for reducing proliferative arterial diseases.
The atherosclerotic lesion is characterized by the endothelial
dysfunction, inflammation, and accumulation of vascular
smooth muscle cells (SMCs),3 foam cells, and matrix protein
and lipids in the intima (1, 2). Although the pathogenic mech-
anisms of atherosclerosis and restenosis are complex, the bal-
ance between proliferation and apoptosis of vascular SMCs
seems to be a major factor in the progression of these diseases
(1, 2). Various growth factors and cytokines are known to be
involved in these processes (3–6). One important pleiotropic
cytokine is tumor necrosis factor- (TNF-), which is believed
to play a key role in modulating SMC proliferation, migration,
survival, or apoptosis (3–6). TNF-has been shown to promote
cellular proliferation and survival via phosphoinositide 3-ki-
nase (PI3K)/Akt and nuclear factor-B signaling pathways in
several cell types (7–10). ActivatedAkt phosphorylates and reg-
ulates a number of downstream proapoptotic proteins, among
which are the forkhead factors FoxO1, FoxO3a, and FoxO4 (for-
mally known as FKHR, FKHRL1, and AFX, respectively) (11).
The FoxO proteins aremultifunctional transcription factors,
which have important roles in regulating cellular differentia-
tion, proliferation, survival in various cell lines, including can-
cer cells, fibroblasts, myoblasts, endothelial cells, and SMCs
(3–6). Activated FoxO proteins modulate apoptosis through
regulation of a number of proapoptotic proteins, inducing Bim,
the TNF-related death inducing ligand, Fas ligand, and TNF-
R1-associated death domain,which all are involved in apoptotic
signaling (11–14). Recent studies demonstrate that FoxOs are
expressed in the vasculature and exert a growth-suppressive
effect in endothelial cells and SMCs via p27Kip1-dependent
cycle arrest and apoptosis, thereby inhibiting neointimal for-
mation (4, 6, 15).
FoxO1 proteins lie downstream of TNF-, platelet-derived
growth factor-BB, and insulin-like growth factor 1 signaling
pathways in SMCs in vitro, and treatment with these growth
factors stimulates Akt-dependent phosphorylation and nuclear
exclusion of FoxOs to the cytoplasm where they are inactive
through the ubiquitin-proteasome system (16–20). Impor-
tantly, FoxO1 has been shown to be targeted by the F-box pro-
tein Skp2 for proteasomal degradation, and this effect of Skp2
requires Akt-specific phosphorylation of FoxO1 (18), indicat-
ing that protein phosphorylation and subsequent proteasomal
degradation are key steps for FoxO1 inactivation in SMCs.
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However, little information is known about the ubiquitin ligase
necessary for FoxO1 degradation in SMCs in response to
TNF-.
C terminus of Hsc70-interacting protein (CHIP) was
recently identified as a dual-function cochaperone/ubiquitin
ligase that is highly expressed in the heart, vascular cells, and
other cells (21–23). CHIP is demonstrated to target chaper-
one-bound client proteins such as p53 (24), ErbB2 (25), cys-
tic fibrosis transmembrane conductance regulator (26, 27), Tau
(28, 29), ASK1 (30), and ataxin-1
(31, 32) for the ubiquitin-mediated
degradation. Recently, CHIP has
been reported to play an impor-
tant role in preventing cell apopto-
sis. CHIP-deficient mice undergo
temperature-sensitive apoptosis
after environmental stress (33).
CHIP also displays a critical cardio-
protective effect in response to
ischemia/reperfusion injury (34).
Furthermore, CHIP inhibits ASK1-
mediated apoptosis via its degrada-
tion (30). More recently, we found
that CHIP promotes myocardin
ubiquitin-mediated degradation
and attenuates myocardin-depend-
ent SMC differentiation (35). How-
ever, the role of CHIP in TNF--in-
duced SMC proliferation and
survival has not been examined. In
the present study, we showed that
CHIP interactedwith andpromoted
ubiquitin-dependent degradation of
FoxO1, thereby repressing FoxO1-
induced anti-proliferation and apo-
ptosis in SMCs following TNF-
treatment. In contrast, depletion of
CHIP by small interfering RNA
attenuated the inhibitory effect of
FoxO1 on SMC proliferation and
survival. Thus, CHIP appears to
have an important role in regulating




sion plasmids Myc-CHIP wild type
and mutants, His- or HA-ubiquitin,
and Bim luciferase reporter, FLAG-
FoxO1 wild-type and mutants,
HA-FoxO3a and FLAG-FoxO4
have been described previously
(18, 21, 33, 36, 37). The pEGFP
vector was purchased from BD
Biosciences (Clontech). siRNA
sequences for CHIP was described
as previously (30). All mutated
clones were verified by fully sequencing.
Antibodies and Chemicals—The following antibodies were
used: anti-CHIP (H-231) and anti-Myc (clone 9E10, Santa Cruz
Biotechnology), anti-FLAG (M2, Sigma-Aldrich), anti-HA
(clone 12CA5, RocheDiagnostics), anti-GST (AmershamPhar-
macia Biosciences), anti-ubiquitin and anti-His (Chemicon
International Inc.), anti-AKT, anti-phospho-AKT (Ser-473),
anti-FoxO1, anti-phospho-FoxO1 (Ser-256), anti-FoxO3a,
anti-FoxO4, anti-GAPDH, and horseradish peroxidase-conju-
FIGURE 1. CHIP decreases FoxO1 protein level. A, SMCs were transfected with Myc-CHIP or vector and treated
with TNF- (10 ng/ml) for 24 h. Whole cell extracts were subjected to immunoblot analysis using antibodies
against Akt, FoxO1, FoxO3a, FoxO4, CHIP, and GAPDH (as a loading control). B, SMCs were transfected with
increasing amounts of Myc-CHIP and treated with TNF- (10 ng/ml) for 24 h. Whole cell extracts were prepared
for Western blot analysis as in A. C and D, human umbilical endothelial cells or cardiomyocytes were infected
with adenovirus Myc-CHIP or vector control and treated with TNF- (10 ng/ml) for the indicated time points.
Whole cell extracts were subjected to immunoblot analysis using antibodies against FoxO1, Myc, and GAPDH.
A representative blot is shown (n  3). E, SMCs were transfected with siRNA-control or siRNA-CHIP and treated
with TNF- (10 ng/ml) for 24 h. Whole cell extracts were prepared for Western blot analysis as in A. F, the left
common carotid artery was ligated for 24 days; both right and left common carotid arteries were harvested,
fixed, and stained with anti-CHIP or anti-Foxo1 antibody (arrow indicates neointimal formation in vessels,
original magnification, 100). G, SMCs were transfected with Skp2 and treated as in A. Whole cell extracts were
subjected to immunoblot analysis using antibodies against FoxO1, HA, and GAPDH. A representative blot is
shown (n  3). H, SMCs were transfected and treated as in B. Total RNA was isolated, and the expression levels
of transcripts for FoxO1, FoxO3a, and FoxO4 were determined by reverse transcription-PCR analysis, normal-
ized to GAPDH. A representative blot is shown (n  3).
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gated secondary antibody (Cell Signaling Technology). TNF-
was purchased from Sigma-Aldrich. Cycloheximide, wortman-
nin, and MG-132 were purchased from Calbiochem.
Cell Culture, Transfection, and Luciferase Assays—293T, rat
aortic smooth muscle cells A10 and human umbilical endothe-
lial cells (human umbilical endothelial cells) were obtained
from ATCC (Manassas, Virginia) and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum at 37 °C as described (38). Rat neonatal cardiomyocytes
were isolated by enzymatic disassociation of 1- to 2-day-old
neonatal rat hearts as described previously (38). Recombinant
adenoviruses vector control and Myc-tagged CHIP were gen-
erated as described previously (35).
Cycloheximide, MG132, or TNF- was added at a final con-
centration of 10 g/ml, 10 M, or 10 ng/ml, respectively. The
luciferase reporter constructs were cotransfected using Lipo-
fectamine 2000 (Invitrogen) with expression vectors carrying
CHIP wild type or mutants, FoxO1 expression vectors into
293T cells or with siRNA CHIP into A10 cells, and luciferase
activity was measured as described previously (38). The data
represent means  S.E. of three independent experiments in
duplicate and normalization for -galactosidase activity.
Cell Viability, Apoptosis, and Pro-
liferation Assays—Cell viability was
determined by Trypan blue exclu-
sion assay. Cell apoptosis was
detected by TUNEL assay using an
in situ apoptosis detection kit
(Roche Applied Science) following
the manufacturer’s instructions.
Percentages of positive-stained cells
were determined by counting the
numbers of labeled and total cells.
Cell proliferation was determined
by WST-1 assay (Roche Applied
Science) as suggested by the manu-
facturer. SMCs were seeded in
24-well plates and transfected with
the indicated plasmids. At 24 h after
transfection, cells were starved for
overnight and treated with TNF-
for 24 h, and then incubated with
WST-1 for 2 h at 37 °C. Formation
of formazan was directly quanti-
tated with an enzyme-linked immu-
nosorbent assay reader at 460 and
690 nm. The data represent the




as described previously (36). The
visualization of CHIP and FoxO1
location was performed by immu-
nostaining with CHIP or FoxO1
primary antibodies and appropri-
ate secondary antibodies. Fluores-
cent images were collected on
Nikon Eclipse E800 microscope.
Immunoprecipitations, Western Blotting, and GST Pulldown
Assays—Immunoprecipitation and Immunoblotting were per-
formed as described previously (38). Briefly, 293 cells were
cotransfected with expression vectors for Myc-CHIP,
FLAG-FoxO1. Tagged proteins were immunoprecipitated
for 2 h at 4 °C with the appropriate antibody (anti-Myc). The
beads were washed and analyzed by immunoblotting. GST
pulldown assays were performed as described (38). Briefly,
293 cells were transfected with FLAG-FoxO1 expression
plasmid for 36 h, and cells were lysed for 30 min in lysis
buffer. Lysates were precleared with GST beads for 1 h and
incubated with GST or GST-CHIP fusion proteins for 1 h at
4 °C. The bound beads were washed four times with lysis
buffer and analyzed by immunoblotting.
Pulse-Chase Assays—To analyze the degradation kinetics of
FoxO1, 293T cells were seeded in 6-well plates and were trans-
fected with FLAG-FoxO1 and Myc-CHIP or vector as indi-
cated. Protein lysates were prepared at indicated time points
after addition of cycloheximide (10 g/ml). Cells were washed
twice in phosphate-buffered saline and lysed in immunopre-
cipitation lysis buffer. Equal amounts of protein were separated
FIGURE 2. CHIP promotes ubiquitination and degradation of FoxO1. A, 293 cells were cotransfected with
FLAG-FoxO1, vector control, or Myc-CHIP and treated with cycloheximide (Chx, 10 g/ml) for the indicated
time points. Equal amounts of cell lysates were subjected to SDS-PAGE. The level of protein was detected by
Western blotting with anti-FLAG, anti-Myc, or anti-GAPDH antibodies (top). The amount of FoxO1 in presence
of CHIP (squares) and absence of CHIP (triangle) was quantified. Values shown are the means  S.E. of three
independent experiments (bottom). B, SMCs cotransfected with Myc-CHIP or vector were treated with TNF-
(10 ng/ml) in the absence or presence of MG132 for 6 h. Whole cell extracts were prepared for Western blot
analysis using FoxO1, Myc, and GAPDH antibodies (top). Values shown are the means  S.E. of three independ-
ent experiments (bottom). *, p  0.01 versus vector. C, 293 cells were cotransfected with His-ubiquitin (His-Ub),
FLAG-FoxO1, and Myc-CHIP and treated with TNF- (10 ng/ml) for 24 h and MG132 for 6 h. Cell lysates were
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-His (top) or anti-FLAG (bottom)
antibodies. D, 293 cells were cotransfected and treated as in C. Whole cell extracts were subjected to direct
immunoblot analysis using anti-FLAG or anti-Myc antibodies, and GAPDH as loading controls.
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by SDS-PAGE. Levels of FoxO1 proteins were determined by
immunoblotting and quantified at indicated time points.
In Vivo Ubiquitination Assays—To assess ubiquitination in
vivo, 293 cells were transfected with His-Ub or HA-Ub, FLAG-
FoxO1, andMyc-CHIP and treatedwith TNF- for 24 h. Lysate
proteins were precipitated and analyzed by immunoblotting
using appropriate antibodies as previously described method
(38).
RNA Analysis—Total RNA was purified from cultured cells
withTRIzol (Invitrogen). Reverse transcription-PCRanalysis of
transcripts of FoxO1, FoxO3a, FoxO4, Bim, p27kip1, GADD45,
and GAPDH (as a control) was performed with primers
designed to detect rat gene products as described previously
(37, 38).
Carotid Artery Ligation and Immunohistochemistry—The
carotid artery was isolated from anesthetized 2-month-old
male rat by using an approved institutional protocol according
to Peking Union Medical College guidelines. Carotid artery
ligation was performed as described previously (39). 24 days
after ligation, the left and right carotid arteries were harvested,
fixed, and stained using anti-CHIP or anti-FoxO1 antibody
(1:50) following standard protocol.
Statistical Analysis—Data are presented asmeans S.E. Dif-
ferences between groups were evaluated for statistical signifi-
cance using Student’s t test. p values 0.05 were regarded as
significant.
RESULTS
CHIP Down-regulates FoxO1 Expression—It has been dem-
onstrated previously that FoxO1, FoxO3a, and FoxO4 can be
degraded by the ubiquitin-proteasome pathway in several cell
types (16–20). We hypothesized that CHIP as an E3 ligase
might be involved in this proteolysis, thereby modulating SMC
proliferation and apoptosis. To test this hypothesis, we first
investigated whether CHIP affected the expression of Akt and
FoxO proteins in SMCswithout or with TNF- stimulation. As
shown in Fig. 1A, overexpression of CHIP decreased the level of
endogenous FoxO1 protein, and this effect was further
enhanced by TNF-. Moreover, CHIP had a dose-dependent
inhibitory effect on the level of endogenous FoxO1 protein (Fig.
1B). In contrast, CHIPwas unable to down-regulate the expres-
sion of FoxO3a and FoxO4 (Fig. 1,A andB). Furthermore, over-
expression of CHIPwas found to decrease expression of endog-
enous FoxO1 protein in human umbilical endothelial cells and
rat neonatal cardiomyocytes, although to varying degrees (Fig.
1, C and D). Interestingly, Akt was activated by TNF-, but no
significant change in Akt phosphorylation was observed in
CHIP-transfected cells compared with vector transfection (Fig.
1, A and B). To further test the involvement of endogenous
CHIP in regulating FoxO proteins, we performed gene knock-
down experiments with CHIP siRNA. As shown in Fig. 1E,
depletion of endogenous CHIP resulted in an increase of
endogenous FoxO1 protein, whereas transfectionwith nonspe-
cific siRNA had no effect. Collectively, these results indicate
that the inhibitory effect of CHIP on the expression of FoxO1
was specific.
Importantly, immunohistochemical staining for CHIP and
FoxO1 was performed in the neointimal layer of the rat carotid
artery following flow cessation injury. As shown in Fig. 1F,
CHIP expression was up-regulated, whereas FoxO1 was
decreased compared with the control uninjured artery.
Because Skp2 also targets FoxO1 for proteasomal degrada-
tion in LNCaP, NIH 3T3, and COS7 cell (18), we further inves-
tigated whether Skp2 down-regulated FoxO1 level in SMCs.
Overexpression of Skp2 did not significantly decrease FoxO1
protein in SMCs without or with TNF- stimulation (Fig. 1G).
Thus, it appears that Skp2 has a veryminimal effect on FoxO1
protein level in SMCs.
To elucidate the underlying mechanism, we examined
whether CHIP regulated the expression of FoxO1 at the mes-
senger level by using reverse transcription-PCR. CHIP did not
affect the mRNA level of FoxO1, FoxO3a, and FoxO4 (Fig. 1H).
Taken together, these results suggest that CHIP specifically
down-regulates FoxO1 expression in SMCs at protein level.
CHIP Targets FoxO1 for Ubiquitination-mediated Degrada-
tion—To determine whether CHIP as an E3 ligase promotes
ubiquitination and degradation of FoxO1, we performed a
pulse-chase assay and found that overexpression of CHIP
resulted in a rapid decrease in the FoxO1 protein compared
with vector control (Fig. 2A). In contrast, treatment with pro-
teasome inhibitor MG132 significantly blocked CHIP-induced
down-regulation of FoxO1 protein despite of TNF- treatment
(Fig. 2B). Furthermore, CHIP markedly promoted ubiquitina-
tion and degradation of FoxO1, and this effect was enhanced
markedly by TNF- (Fig. 2, C and D). These results demon-
strate that CHIP targets FoxO1 for proteasomal degradation,
which is triggered by TNF-.
FIGURE 3. CHIP interacts with FoxO1. A, lysates of 293T cells transfected with
FLAG-FoxO1, HA-FoxO3a, and FLAG-Foxo4 were subjected to GST pulldown
assay by GST-CHIP or GST alone fusion protein, and bound proteins were
analyzed by immunoblotting using anti-FLAG or anti-HA antibody after bind-
ing reactions. B, SMCs treated without or with MG132 for 12 h were immuno-
precipitated with anti-CHIP antibody or control IgG, and the immunoprecipi-
tates were subjected to SDS-PAGE and immunoblotted with anti-FoxO1
antibody. C, SMCs were cotransfected with the indicated plasmids, and whole
cell lysates were immunoprecipitated (IP) with anti-Myc antibody or control
IgG. Immunoprecipitates were analyzed by immunoblotted with anti-FLAG
and anti-Myc antibodies. D, immunostaining analysis of endogenous CHIP
and FoxO1 in SMCs showed that CHIP colocalized with FoxO1.
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CHIP Interacts with FoxO1—Because one of the characteris-
tics for an E3 ligase is the recognition of specific substrates, it
will be interesting to test whether CHIP is physically associated
with FoxO1. GST pulldown assays showed that FoxO1 (but not
FoxO3a or FoxO4) more strongly bound to GST-CHIP (Fig.
3A). Coimmunoprecipitation assays confirmed that anti-CHIP
precipitated FoxO1, and this interaction was enhanced by
MG132 (Fig. 3B). Moreover, FLAG-FoxO1 was detected in the
Myc-CHIP immune complex, whereas no FLAG-FoxO1 was
found in the immune complex precipitated with a nonspecific
IgG (Fig. 3C). Finally, immunostaining demonstrated that
CHIP was colocalized with FoxO1 in cytoplasm of SMCs (Fig.
3D). These data indicate that CHIP specifically interacts with
FoxO1 in vivo and in vitro.
Both the U-box and Charged Domains Are Essential for
CHIP-induced Ubiquitination and Degradation of FoxO1—To
map the FoxO1 binding region of CHIP, we performed GST
pulldown assays using a series of GST-fusion CHIP deletion
mutants and FoxO1 expressed in 293T cells. Full-length CHIP
efficiently interacted with FoxO1, and deletion of the U-Box
domain (198–303aa) had less effect on CHIP binding to
FoxO1. However, deletion of the
charged domain (143–197aa)
completely abolished the binding of
CHIP to FoxO1 in this assay (Fig. 4,
A and B), indicating that residues
between 143 and 197 of CHIP are
sufficient to bind FoxO1.
To further examine whether the
ubiquitin ligase activity and FoxO1
interaction domain are required for
CHIP-mediated FoxO1 degrada-
tion, three CHIP mutants were
used. As shown in Fig. 4 (C and D),
both CHIP Wt and TPR (1–
142aa) significantly increased ubiq-
uitination of FoxO1 and down-reg-
ulated its protein levels. In contrast,
neither CHIP U-box (198–
303aa) nor (143–197aa) mu-
tant had any effect, indicating that
both U-box and charged domains
in CHIP are involved in ubiquiti-
nation and degradation of FoxO1
proteins.
CHIP-induced Ubiquitination of
FoxO1 Requires Phosphorylation of
FoxO1 at S256—Because PI3K/Akt-
dependent phosphorylation plays a
key role in the proteasomal degra-
dation of FoxO1 (17–19, 40), we
determined whether TNF- mod-
ulates FoxO1 phosphorylation
through PI3K/Akt signaling path-
way in SMCs. As shown in 5A, incu-
bation of SMCs with TNF- for 30
min resulted in markedly phospho-
rylation of Akt and FoxO1, and this
effect was completely blocked by pretreatment with the PI3K
inhibitor wortmannin. This is consistent with the notion that
FoxO1 acts downstream of Akt phosphorylation in the PI3K/
Akt pathway.
CHIP has been known to preferentially recognize phospho-
rylated substrates such as Tau (28, 29), we therefore examine
whether ubiquitination of FoxO1 by CHIP requires its phos-
phorylation in vivo. As shown in Fig. 5B, treatment with TNF-
increased the level of Akt phosphorylation and decreased total
and phosphorylated FoxO1 protein in a time-dependent man-
ner, indicating that TNF- induced degradation of FoxO1 via
Akt activation. We next examined whether mutation of the
Akt-phosphorylation sites at Thr-24, Ser-256, and/or Ser-319
to alanine affects the interaction of FoxO1withCHIP. All of the
mutant forms of FoxO1 were expressed at comparable levels in
293T cells (Fig. 5C, bottom). Both T24A and S319A mutants
were able to form a complex with CHIP. However, the interac-
tion between FoxO1 and CHIP was almost abolished by a point
mutation at S256A or triple mutations A3 at T24A, S256A, and
S319A (Fig. 5C, top).Moreover, ubiquitinationwas observed on
the FoxO1 or mutants at position either T24A or S319A,
FIGURE 4. Both the U-Box and charged domains are required for CHIP-induced FoxO1 ubiquitination and
down-regulation. A, the residues of CHIP required for binding to FoxO1 were determined with GST pulldown
assays. GST-CHIP fusion proteins were purified from bacteria and analyzed by immunoblotting with GST anti-
body (top). The ability of the truncated CHIP fusion proteins to bind to FLAG-FoxO1 expressed in 293T cells was
analyzed by blotting with anti-FLAG antibody (middle). 10% of input was shown in the bottom panel. B, sche-
matic representation of CHIP truncations that interact with FoxO1. TPR, tetratricopeptide repeat domain; /,
charged region; U-Box, U-box domain. C, 293T cells were transfected with HA-ubiquitin, FLAG-FoxO1, CHIP Wt,
or mutants plasmids in the presence of TNF- (10 ng/ml) for 24 h and MG132 for 6 h. Cell extracts were
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-HA (top) or FLAG (bottom) anti-
bodies. D, 293T cells were transfected with the indicated plasmids and treated with TNF-. Whole cell extracts
were subjected to direct immunoblot analysis using anti-FLAG or anti-Myc antibodies, and GAPDH as loading
controls.
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whereas ubiquitination of FoxO1 was diminished by the single
mutation at S256A or triple mutations A3 (Fig. 5D).
We next investigated the effect of CHIP on the protein sta-
bility of FoxO1Wt and its mutants. Cells were transfected with
CHIP and with FoxO1Wt or mutants with TNF- stimulation
for 24 h. Overexpression of CHIP markedly decreased FoxO1
Wt, T24A, and S319A protein levels, whereas the CHIP had no
effect on FoxO1 S256A and A3 following TNF- treatment
(Fig. 5E). Together, these findings demonstrate that interac-
tion, ubiquitination, and degradation of FoxO1 by CHIP
depend on its phosphorylation at Ser-256.
CHIP Inhibits FoxO1-mediated Gene Transactivation—Af-
ter having established a role for CHIP in FoxO1 protein turn-
over, we next examined the effect of CHIP on FoxO1-mediated
gene transactivation. A luciferase assay was performed using
Bim reporter, FoxO1, and CHIP. As shown in Fig. 6 (A and B),
CHIP inhibited the transcriptional activity of FoxO1 in a dose-
dependentmanner. TNF- treatment alone also attenuated the
transcriptional activity of FoxO1. Moreover, the inhibition of
FoxO1 transactivation was enhanced by the combination of
CHIP and TNF-. Interestingly, the single mutation of FoxO1
at Ser-256 resulted in a higher transactivation activity of
FoxO1. In contrast to the wild-type FoxO1, there was no effect
of CHIP expression on transcriptional activity of FoxO1 S256A.
However, treatment with TNF- decreased the activity of
FoxO1 S256A (Fig. 6C). This is presumably due to activation of
Akt by TNF-, resulting in FoxO1 phosphorylation at Thr-24
and Ser-319 and inactivation. Interestingly, expression of
FoxO1 A3 caused an over 3-fold increase in its transactivation
when compared with the wild-type FoxO1, and FoxO1 A3
mutant was resistant to CHIP- or TNF--induced down-regu-
lation of transactivation (Fig. 6D).
To further investigate the functional role of endogenous
CHIP in FoxO1-mediated transactivation in SMCs, we
depleted endogenous CHIP protein using siRNA and per-
formed luciferase assay with Bim reporter. As shown in Fig. 6E,
transcriptional activity of the Bim reporter by FoxO1 was
increased 2-fold by siRNA-CHIP than scrambled siRNA-
control. Furthermore, the mRNA expression of known FoxO
target genes, including Bim, p27kip1, and GADD45 was con-
comitantly increased in siRNA-CHIP transfected cells. Quanti-
tative analysis indicated that the expression of each of these
target genes was increased by 1.8-fold or more in siRNA-
CHIP-transfected cells compared with siRNA-control cells
(Fig. 6F). Taken together, these data suggest that CHIP nega-
tively regulates the transcriptional activity of FoxO1 through
proteasomal degradation.
CHIP Blocks FoxO1-mediated Apoptosis and Growth Arrest
of SMCs—To investigate a functional role of CHIP in FoxO1-
mediated cell growth arrest and apoptosis, we performed cell
viability and proliferation assays. As shown in Fig. 7 (A and B),
similar to previous data (4), overexpression of FoxO1 Wt and
S256Amutant resulted in a significant decrease of viability and
proliferation in SMCs, and the effect of FoxO1 Wt was mark-
edly abolished by cotransfection of CHIP. However, no action
was observed when cells were cotransfected with CHIP and
FoxO1 S256A mutant. Moreover, TNF- treatment increased
CHIP-mediated SMCviability and proliferation in the presence
of FoxO1 Wt and S256A mutant. Furthermore, depletion of
endogenous CHIP by siRNAs markedly increased protein level
of FoxO1, cleaved caspase-3 and poly(ADP-ribose) polymerase
compared with siRNA-control (Fig. 7C), and this effect was
further enhanced with TNF- stimulation. More importantly,
CHIP knockdown promoted FoxO1-induced cell apoptosis
(Fig. 7D) and decreased cell proliferation in SMCs (Fig. 7E).
These results indicate that CHIP is a negative regulator for
FoxO1-induced growth arrest and apoptosis in SMCs.
DISCUSSION
It is now recognized that the balance between proliferation
and apoptosis is linked to various vascular diseases, such as
atherosclerosis and neointimal hyperplasia after vascular inter-
vention. FoxO1, a main member of the forkhead transcription
factor family, has been shown to play an important role in cell
cycle arrest and apoptosis of various cell lines (41). In the pres-
ent study, we demonstrated that the protein level of FoxO1 is
tightly controlled by CHIP through ubiquitin-mediated degra-
dation following TNF- treatment, and this effect of CHIP
requires phosphorylation of FoxO1 at Ser-256. Importantly,
overexpression of CHIP represses FoxO1-mediated transacti-
vation and its inhibitory function on SMC survival and prolif-
eration. In contrast, deletion of CHIP by siRNA had opposite
effects. Thus, we have identified a previously uncharacterized
mechanism of inactivation of FoxO1 by CHIP in SMCs.
FIGURE 5. CHIP-induced ubiquitination of FoxO1 requires phosphoryla-
tion of FoxO1 at Ser-256. A, SMCs were pretreated with wortmannin (200
nM) for 30 min and then incubated with TNF- (10 ng/ml) for further 30 min.
Whole cell extracts were subjected to direct immunoblot analysis using anti-
FoxO1, anti-Akt, and anti-GAPDH antibodies. B, SMCs were treated with
TNF- (10 ng/ml) for 0 –24 h. Whole cell extracts were detected as in A.
C, lysates of 293T cells transfected with FLAG-FoxO1 Wt or mutants (T24A,
S256A, S316A, or A3) were subjected to GST pulldown by GST-CHIP purified
from bacteria (top). 10% of input is shown in the bottom panel. D, 293T cells
were cotransfected with HA-ubiquitin, CHIP, and FoxO1 mutants plasmids
and treated with TNF- for 24 h and MG132 for 6 h. Cell lysates were immu-
noprecipitated with anti-FLAG antibody and immunoblotted with anti-HA
(top) or anti-FLAG (bottom) antibodies. E, 293T cells were transfected with the
indicated plasmids and treated with TNF- for 24 h. Whole cell extracts were
subjected to direct immunoblot analysis using anti-FLAG or anti-Myc anti-
bodies, and GAPDH as loading controls.
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The significance of the FoxO family members to diverse
physiological events in the transcription-based function is
extensively investigated (41). Activation of Akt regulates activ-
ity of FoxO1 factor by phosphorylating it at three conserved
serine/threonine residues (Thr-24, Ser-256, and Ser-319). This
leads to the release of FoxO1 from DNA and translocation to
the cytoplasm. In the absence of growth or survival signal stim-
ulation, inactivation of Akt in the quiescent cells results in
nuclear retention of FoxO factors, thereby enhancing expres-
sion of its downstream target genes by binding to other tran-
scription factors or acting as an activator that modulate the
metabolic state, DNA repair (e.g. GADD45), cell cycle transi-
tions (e.g. p27kip1), or cellular apoptosis (e.g. Fas ligand, TNF-
R1-associated death domain, and Bim) (41). Recent studies
have demonstrated that expression of FoxOs inhibits SMC
growth and survival via up-regulation of p27Kip1, leading to
inhibition of neointimal hyperplasia (4, 15, 19). These data indi-
cate that FoxO transcription factors play a pivotal role in regu-
lating SMC proliferation and survival.
FoxO transcription factors are controlled by post-transla-
tional modifications. In addition to phosphorylation, FoxO fac-
tors are also regulated by ubiquiti-
nation (41). It has been shown that
steady-state levels of FoxO1 are
reduced in several cell lines in
response to growth and survival fac-
tors such as insulin, insulin-like
growth factor 1, and platelet-de-
rived growth factor, and this effect is
inhibited by proteasome inhibitors,
suggesting that proteasome-medi-
ated degradation of FoxO1 depends
on Akt activation (4, 15–19).
Recently, Abid et al. have shown
that TNF- induces phosphoryla-
tion of FoxO1 proteins on con-
served Akt phosphorylation site
Ser-256 in human coronary ar-
tery SMCs and induces nuclear
exclusion of FoxO1 (4). However, it is
not studied whether TNF--induced
phosphorylation is required for the
ubiquitination of FoxO1, and the E3
ligase responsible for this event is also
unknown.
CHIP as ubiquitin ligase com-
prises three functional domains: a
tetratricopeptide repeat (TPR) at
the N terminus, a U-box domain at
the C terminus, and a highly
charged region (21). CHIP has been
shown to play a critical regulatory
function in the protein quality con-
trol machinery of the cell lines (21–
24, 42) and implicated in the
pathology of several neurological
disorders characterized by protein
misfolding and aggregation (29, 32).
It is believed that CHIP exerts biological effects via inducing
chaperone client proteins for proteasomal degradation.
Recently, we reported that CHIP inhibited myocardin-induced
SMC differentiation via ubiquitin-proteasome system (35). In
the present study, we found that CHIP interacted and down-
regulated FoxO1 protein level through ubiquitin-mediated
degradation, and this effect is enhanced by TNF- treatment
(Figs. 1–3). Moreover, CHIP-induced ubiquitination and deg-
radation of Foxo1 requires its E3 ligase activity (U-box) and
FoxO1 binding domain (charged region) (Fig. 4, C and D). In
accordance with the ubiquitination data in vivo, we further
demonstrated that CHIP overexpression dramatically de-
creases FoxO1-mediated transactivation that is further
enhanced byTNF- (Fig. 6,A andB). In contrast, knockdownof
CHIP increased FoxO1-mediated transactivation and the
expression of FoxOs target genes (Fig. 6, E and F). These find-
ings demonstrate that the cellular protein level and activity of
FoxO1 are tightly controlled by CHIP.
Phosphorylation is required for the ubiquitination of many
transcriptional factor proteins, and in several cases the target
proteins are first marked by phosphorylation for ubiquitina-
FIGURE 6. CHIP inhibits FoxO1-mediated transcriptional activity. A, 293T cells were transfected with Bim
luciferase reporter, FLAG-Foxo1, and increasing amounts of Myc-CHIP (0.25, 0.5, and 1.0 g). 24 h after infec-
tion, Cells were harvested and luciferase activity was measured (n  3, means  S.E.). *, p  0.01 versus FoxO1
alone. B, 293T cells were transfected with Bim luciferase reporter, FLAG-FoxO1, and Myc-CHIP, and cells were
treated without or with TNF- (10 ng/ml) for 24 h. The luciferase analysis was performed as in A. *, p  0.01
versus FoxO1 alone. C, 293T cells were transfected with Bim luciferase reporter, FoxO1 S256A, and Myc-CHIP,
and cells were treated without or with TNF- for 24 h. The luciferase analysis was performed as in A. *, p  0.01
versus FoxO1 S256A alone. D, 293T cells were transfected with Bim luciferase reporter, FoxO1 A3, and Myc-CHIP,
and cells were treated without or with TNF- for 24 h. The luciferase analysis was performed as in A. E, SMCs
were transfected with Bim luciferase reporter, siRNA-CHIP, or siRNA-control. The luciferase activity was deter-
mined (n  3, means  S.E.). *, p  0.01 versus siRNA-control. F, SMCs cells were transfected with siRNA-CHIP or
siRNA-control vector and treated with TNF- (10 ng/ml) for 24 h. Total RNA was isolated and the expression
levels of transcripts for CHIP, Bim, p27Kip1, and GADD45 were determined by reverse transcription-PCR analysis,
normalized to GAPDH (n  3).
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tion. For example, Tau is first phosphorylated by glycogen syn-
thase kinase 3 and then targeted to proteasomal degradation
byCHIP (28, 29, 43). Indeed, it is evident that FoxOproteins are
regulated by the PI3K/Akt pathway, and the phosphorylation of
FoxO proteins by Akt results in their cytoplasmic retention and
proteasomal degradation (4, 16–19). More recently, Skp2, an
oncogenic subunit of the Skp1/Cul1/F-box protein ubiquitin
complex, was shown to interact with and promote the degrada-
tion of Foxo1 that requires Akt-induced phosphorylation of
FoxO1 at Ser-256 (18). Consistent
with these findings, our study dem-
onstrated that TNF- can induce
PI3K-dependent activation of Akt,
leading to FoxO1 phosphorylation
and degradation (Fig. 5, A and B).
Importantly, phosphorylation at
position Ser-256 of FoxO1 was
required for its interaction with
CHIP and ubiquitin-mediated deg-
radation (Fig. 5,C–E). Furthermore,
TNF- treatment alone markedly
decreased FoxO1 S256A-mediated
transactivation. However, CHIP had
no this effect (Fig. 6C). These data
indicate that CHIP selectively pro-
motes ubiquitination and degrada-
tionof phosphorylatedFoxO1 in vivo.
Recent studies demonstrate that
CHIP-deficient mice develop apop-
tosis in cardiomyocytes and espe-
cially endothelial cells of intramural
vessels in response to ischemia-
reperfusion injury (33, 34). CHIP
degrades ASK1 and inhibits JNK
activation in response to oxidative
stress (30). Furthermore, CHIP
cooperates with E2 enzymes of the
Ubc4/5 family tomediate ubiquitin-
mediated proteasomal degradation
of chaperone-bound p53 (24).
These observations led us to search
for a mechanism whereby CHIP
might be directly involved in apo-
ptosis in the face of cellular stress.
Indeed, the present studies extend
these observations by demonstrat-
ing a functional role of endogenous
CHIP in FoxO1-mediated apoptotic
signaling and cell proliferation.
Overexpression of CHIP signifi-
cantly attenuated the effect of
FoxO1Wt on viability and prolifer-
ation of SMCs without or with
TNF- treatment (Fig. 7, A and B).
However, no effect was observed
when cells were cotransfected with
CHIP and FoxO1 S256A mutant
(Fig. 7, A and B). In contrast, deple-
tion of CHIP increased the level of cleaved caspase-3 and poly-
(ADP-ribose) polymerase (Fig. 7C), resulting in a significant
increase of apoptosis and decrease of proliferation in SMCs via
activation of FoxO1 (Fig. 7, D and E), indicating that CHIP
participates in inhibiting FoxO1-mediated apoptosis and
growth arrest in SMCs.
In conclusion, our data strongly indicate that CHIP regulates
phenotypic modulation of SMC through ubiquitination and
degradation of FoxO1. Based on these findings, we propose a
FIGURE 7. CHIP antagonizes the proapoptotic and anti-proliferative function of FoxO1. A, SMCs cells were
cotransfected with vector pcDNA-GFP, GFP-FoxO1 wt, or GFP-FoxO1 S256A mutant in the presence or absence
of CHIP and treated without or with TNF- (10 ng/ml) for 24 h. Transfected viable cells were photographed
under both UV and transmitted light. Quantitative data of viable cells were determined using trypan blue assay
from three independent experiments in A. *, p  0.01 versus vector. B, SMCs were transfected and treated as in
A, cell proliferation was performed using WST-1 assay. *, p  0.01 versus vector control. C, cells were transfected
with siRNA-CHIP or siRNA-control and treated without or with TNF- for 24 h. The protein levels of CHIP, FoxO1,
cleaved caspase 3, and poly(ADP-ribose) polymerase (PARP) were examined by immunoblotting with antibod-
ies as indicated. D, SMCs were cotransfected with control vector or wild-type FoxO1 in the presence of siRNA-
control or siRNA-CHIP and treated with TNF- for 24 h. To quantify apoptotic cells, cells were fixed and stained
with TUNEL. At least 120 cells per dish were counted. Results were expressed as means  S.E. for three inde-
pendent experiments. #, p  0.05 or *, p  0.01 versus siRNA-control. E, SMCs were transfected and treated as in
D, and cell proliferation analysis was performed using WST-1 assay. Results were expressed as means  S.E. of
three separate experiments. #, p  0.05 or *, p  0.01 versus siRNA-control. F, proposed mechanisms for CHIP to
regulate SMC proliferation and survival through ubiquitination and degradation of FoxO1 by the proteasome.
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novel model to explain the involvement of CHIP in enhancing
proliferation and survival of SMCs in response to TNF- (Fig.
7F). TNF- binds its specific receptor and activates PI3K/Akt
signaling (16, 18), resulting in FoxO1 phosphorylation. CHIP
promotes the ubiquitin-mediated degradation of phosphoryla-
ted FoxO1 proteins, leading to consistently decreased protein
levels and inactivation of FoxO1. Consequently, TNF- stimu-
lates SMC proliferation and survival, resulting in neointimal
formation. This study reveals the importance of CHIP in pro-
liferation and survival of SMCs and suggests that itmay serve as
a target for interventions in pathological states. Future studies
are required to confirm the molecular mechanisms by which
CHIP promotes degradation of FoxO1 and regulates pheno-
typic modulation of vascular SMCs in animal model.
REFERENCES
1. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Physiol. Rev. 84,
767–801
2. Owens, G., Emons, M. F., Christian-Herman, J., and Lawless, G. (2007)
Dis. Manag. 10, 74–82
3. Potente,M., Urbich, C., Sasaki, K., Hofmann,W. K., Heeschen, C., Aicher,
A., Kollipara, R., DePinho, R. A., Zeiher, A. M., and Dimmeler, S. (2005)
J. Clin. Invest. 115, 2382–2392
4. Abid, M. R., Yano, K., Guo, S., Patel, V. I., Shrikhande, G., Spokes, K. C.,
Ferran, C., and Aird, W. C. (2005) J. Biol. Chem. 280, 29864–29873
5. Abid, M. R., Shih, S. C., Otu, H. H., Spokes, K. C., Okada, Y., Curiel, D. T.,
Minami, T., and Aird, W. C. (2006) J. Biol. Chem. 281, 35544–35553
6. Park, K. W., Kim, D. H., You, H. J., Sir, J. J., Jeon, S. I., Youn, S. W., Yang,
H. M., Skurk, C., Park, Y. B., Walsh, K., and Kim, H. S. (2005) Arterioscler.
Thromb. Vasc. Biol. 25, 742–747
7. Ozes, O. N., Akca, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E.,
and Donner, D. B. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 4640–4645
8. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and
Donner, D. B. (1999) Nature 401, 82–85
9. Osawa, Y., Banno, Y., Nagaki, M., Brenner, D. A., Naiki, T., Nozawa, Y.,
Nakashima, S., and Moriwaki, H. (2001) J. Immunol. 167, 173–180
10. Osawa, Y., Nagaki, M., Banno, Y., Brenner, D. A., Asano, T., Nozawa, Y.,
Moriwaki, H., and Nakashima, S. (2002) Infect. Immun. 70, 6294–6301
11. Van Der Heide, L. P., Hoekman,M. F., and Smidt, M. P. (2004) Biochem. J.
380, 297–309
12. Modur, V., Nagarajan, R., Evers, B. M., and Milbrandt, J. (2002) J. Biol.
Chem. 277, 47928–47937
13. Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y.,
Tran,H., Ross, S. E.,Mostoslavsky, R., Cohen,H. Y., Hu, L. S., Cheng,H. L.,
Jedrychowski, M. P., Gygi, S. P., Sinclair, D. A., Alt, F. W., and Greenberg,
M. E. (2004) Science 303, 2011–2015
14. Gilley, J., Coffer, P. J., and Ham, J. (2003) J. Cell Biol. 162, 613–622
15. Lee, H. Y., Chung, J.W., Youn, S.W., Kim, J. Y., Park, K.W., Koo, B. K., Oh,
B. H., Park, Y. B., Chaqour, B., Walsh, K., and Kim, H. S. (2007) Circ. Res.
100, 372–380
16. Hu,M. C., Lee, D. F., Xia,W., Golfman, L. S., Ou-Yang, F., Yang, J. Y., Zou,
Y., Bao, S., Hanada,N., Saso,H., Kobayashi, R., andHung,M.C. (2004)Cell
117, 225–237
17. Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K., and Fukamizu, A.
(2003) Proc. Natl. Acad. Sci. U.S.A. 100, 11285–11290
18. Huang, H., Regan, K. M., Wang, F., Wang, D., Smith, D. I., van Deursen,
J.M., andTindall, D. J. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 1649–1654
19. Plas, D. R., and Thompson, C. B. (2003) J. Biol. Chem. 278, 12361–12366
20. Brenkman, A. B., de Keizer, P. L., van den Broek, N. J., Jochemsen, A. G.,
and Burgering, B. M. (2008) PLoS ONE 3, e2819
21. Ballinger, C. A., Connell, P.,Wu, Y., Hu, Z., Thompson, L. J., Yin, L. Y., and
Patterson, C. (1999)Mol. Cell. Biol. 19, 4535–4545
22. Connell, P., Ballinger, C. A., Jiang, J., Wu, Y., Thompson, L. J., Höhfeld, J.,
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